PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or	agent's file reference	;						
13175WO/ko			FOR FURTHER AC		See Form PCT/IPEA/416			
International application No.			International filing dat	e (day/month/year)	Priority date (day/month/year)			
PCT/EP2004/003399			31.03.2004	4	02.04.2003			
International 1	International Patent Classification (IPC) or national classification and IPC							
					l de la companya de			
Applicant								
BIOPL	NTA ARZNE	IMITTE	L GMBH					
1. This	s report is the interna	ational prelin	ninary examination rep	ort, established by this I	nternational Preliminary Examining Authority			
			e applicant according to	Article 36.				
2. Thi	s REPORT consists of	of a total of _	6	sheets, including	g this cover sheet.			
3. Thi	s report is also accom	panied by A	NNEXES, comprising:					
a.	(sent to the a	pplicant and	to the International Bu	reau) a total of 6	sheets, as follows:			
					mended and are the basis for this report and/or			
	Instruct		curications authorized t	by this Authority (see Ru	le 70.16 and Section 607 of the Administrative			
					siders contain an amendment that goes beyond			
	the disc Box.	closure in the	international applicati	on as filed, as indicated	in item 4 of Box No. I and the Supplemental			
,	(sent to the I	nternational	Rureau anlu) a total of	(indicate type and numbe	r of electronic carrier(s))			
0.	(Sent to the 1	mernanonai	bureau only) a lotal of	(indicate type and number				
	related thereto	in computer	readable form only a	s indicated in the Sunnle	_ , containing a sequence listing and/or tables mental Box Relating to Sequence Listing (see			
			trative Instructions).	s marcated in the Supple	memai box retaining to bequence bisining (see			
	-	ications relati	ng to the following iten	ns:				
	Box No. I	Basis of the	report					
	Box No. II	Priority						
	Box No. III	Non-establi	shment of opinion with	regard to novelty, invent	tive step and industrial applicability			
	Box No. IV		ty of invention					
	Box No. V		•	35(2) with regard to nove	elty, inventive step or industrial applicability;			
	DOX 140. V		d explanations support		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
	Box No. VI	Certain doo	cuments cited					
<u> </u>	Box No. VII	Certain def	ects in the international	application				
	Box No. VIII Certain observations on the international application							
Date of subn	nission of the demand	1		Date of completion of th	uis report			
Name and m	ailing address of the	IPEA/EP		Authorized officer				
	<u> </u>							
1								
Facsimile N	0.			Telephone No.				

Translation

International application No.
PCT/EP2004/003399

Box	No. I	Basis of the report					
1.		regard to the language, this report is based on the international cated under this item.	al application in the language in v	which it was filed, unless otherwise			
		This report is based on translations from the original language which is the language of a translation furnished for the purpose	e into the following languageses of:	· ,			
		international search (Rule 12.3 and 23.1(b))					
		publication of the international application (Rule 12.4)					
		international preliminary examination (Rule 55.2 and/or	•				
2.	2. With regard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):						
		the international application as originally filed/furnished					
	\boxtimes	the description:		•			
		pages 2,3,5-8		as originally filed/furnished 17.01.2005 with letter			
Ì		pages* 1,4	received by this Authority on	of 17.01.2005			
ļ		pages*	received by this Authority on				
	\boxtimes	the claims:					
		nos.		as originally filed/furnished			
		nos.*	as amended (togethe				
		nos.* _1-16	received by this Authority on	17.01.2005 with letter of 17.01.2005			
		nos.*					
		the drawings:					
		sheets		as originally filed/furnished			
		sheets*	received by this Authority on				
		sheets*					
1		a sequence listing and/or any related table(s) - see Suppleme					
١.	\exists		situal box Relating to sequence L	asung.			
3.		The amendments have resulted in the cancellation of:					
		the description, pages	*				
		the claims, nos.					
		the sequence listing (specify):					
l	_	any table(s) related to sequence listing (specify):					
4.		This report has been established as if (some of) the amendr they have been considered to go beyond the disclosure as file	ed, as indicated in the Supplement	ntal Box (Rule 70.2(c)).			
	the description, pages						
	the claims, nos.						
	the drawings, sheets/figs						
	the sequence listing (specify):						
	any table(s) related to sequence listing (specify):						
*	* If item 4 applies, some or all of those sheets may be marked "superseded."						

International application No.
PCT/EP2004/003399

Box No. II	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability						
	ons whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially have not been examined in respect of:						
	the entire international application						
\boxtimes	claims Nos. 1-16 (in respect of industrial applicability)						
becaus	e:						
\boxtimes	the said international application, or the said claims Nos. 1-16 relate to the following subject matter which does not require an international preliminary examination (specify):						
	reface to the following subject matter which does not require an international premiumary examination (specify).						
	Claims 1-16 relate to subject matter which, in the						
	opinion of this Authority, falls under PCT						
	Rule 67.1(iv). Consequently, no expert opinion has						
	been established in respect of the industrial						
applicability of the subject matter of said claims							
	(PCT Article 34(4)(a)(i)).						
	the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):						
	the claims, or said claims Nos. are so inadequately supported						
	by the description that no meaningful opinion could be formed.						
	no international search report has been established for said claims Nos.						
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:						
	the written form has not been furnished						
:	does not comply with the standard						
	the computer readable form has not been furnished						
	does not comply with the standard						
	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.						
	See Supplemental Box for further details.						

International application No.
PCT/EP2004/003399

Box	No. V			ticle 35(2) with regard to novelty, inventive step or industrial applicability;			
1.	Statement						
:	Novelty	(N)	Claims Claims	1-16			
	Inventiv	ve step (IS)	Claims	1-16	YES		
	Industri	al applicability (IA)	Claims		YES		
			Claims	1-16	NO		
2.	Citations as	nd explanations (Rule	70.7)				
	On the assumption that the priority of the present						
	application is valid, the P document cited in the						
	inter	national s	earch	report has been disregarded during			
	the P	CT procedu	re.				
	Reference is made to the following documents:						
	D1:	WO 02/304	04 A	(KAPOOR RAKESH; BERRUTI ALESSANDRA			
		(CA); BIC	RIGIN	AL FOOD & SCIENCE COR)			
		18 April	2002	(2002-04-18)			
	D2:	US 2002/0	04074	A1 (BAKAL ABRAHAM I ET AL)			
		10 Januar	y 200	2 (2002-01-10)			
	D3:	YOSHINO K	ET A	L: "ANTIOXIDATIVE AND HYPOLIPIDEMIC			
		EFFECTS C	F DIE	TARY GREEN TEA POLYPHENOLS IN DDY			
		MICE FED	FISH	OIL-RICH DIET", SHOKUHIN EISEIGAKU			
		ZASSHI, N	IIPPON	SHOKUHIN EISEI GAKKAI, TOKYO, JP,			
		vol. 39,	no. 3	, June 1998 (1998-06),			
		pages 192	2-198,	XP009033072 ISSN: 0015-6426			
	D4:	DATABASE	WPI S	ection Ch, Week 200205 Derwent			
		Publicati	ons L	td., London, GB; Class B04,			
		AN 2002-0	35004	XP002290855			
	•	& CN 1 31	.1 028	A (WANG X)			
		5 Septemb	er 20	001 (2001-09-05)			
				/			

International application No.
PCT/EP2004/003399

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

D5: CARLSON JOSEPH J ET AL: "The effect of a supplement containing Ginkgo biloba (Gb), fish oil (DHA) and gotu kola (Gk) on platelet function in older healthy adults", FASEB JOURNAL, vol. 16, no. 4, 20 March 2002 (2002-03-20), page A646, XP009034771 & ANNUAL MEETING OF THE PROFESSIONAL RESEARCH SCIENTISTS ON EXPERIMENTAL BIOLOGY; NEW ORLEANS, LOUISIANA, USA; APRIL 20-24, 2002 ISSN: 0892-6638.

Unless stated otherwise, the relevant passages are those cited in the international search report.

PCT Article 33(2): The subject matter of claims 1-16 can
 be considered novel (PCT Article 33(2)).

None of the documents D1 to D5, cited in the international search report, discloses the use of omega-3 fatty acids for increasing the bioavailability of secondary plant ingredients.

PCT Article 33(3): The subject matter of claims 1-16 can
 be considered inventive (PCT Article 33(3)).

The problem addressed by the present invention is that of increasing the bioavailability of secondary plant ingredients.

International application No.
PCT/EP2004/003399

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

The available prior art (D1 to D5) contains nothing to indicate that this problem can be solved by using omega-3 fatty acids, as disclosed in the present application (example 5, table 1).

PCT Article 33(3): The PCT Contracting States do not have uniform criteria for assessing the industrial applicability of claims 1-16 in its present form. Patentability may also depend on the wording of the claims. The EPO, for example, does not recognise the industrial applicability of claims to the medical use of a compound; it may, however, allow claims to the first medical application of a known compound or to the use of such a compound in the manufacture of a drug for a new medical application.